Business Wire

Seoul Viosys: Through Air Purifier and Air Sterilizer Filters, Bacterial Growth and Leakage Occur

Share

Seoul Viosys (“SVC”) (KOSDAQ: 092190), a global optical semiconductor company, conducted a test on air sterilization by air purifiers sold in the market. The test confirms that bacterial growth and its leakage occur through the filters. The Company announced filters in air purifiers and air sterilizers can cause viral infection and virus spread.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221229005046/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

[Figure 1] In-house bacterial culture measurement lab (left) in Seoul Viosys, and result of residual bacteria counting within filters (right) (Graphic: Business Wire)

The Company commissioned a research institute K, an internationally certified testing and research institute, to conduct a ‘test on bacterial residue count’ to check how many germs remain within filters. Air purifiers sold in the market were randomly selected and the filter contamination level was checked. For one gram of filter, an average of 70 CFU (colony forming unit) was confirmed, and for yeast and mold, more than 300 CFU per gram. These numbers are three times higher than the bacteria-permissible level, 100 CFU/g, in wet tissues under the current Cosmetics Act of Korea.

In general, air purifier filters need to be replaced, on a regular basis, every 6 months or every year, as the capture performance of filters is compromised due to suspended particles such as captured dust. According to a thesis on the survival period of harmful bacteria in filters (Survival of Microorganisms on HEPA Filters. James T. Walker et al., Applied Biosafety Vol. 16, No. 3, 2011), it has been confirmed that Staphylococcus epidermidis which causes vomiting, stomachache, and diarrhea can live up to five days in filters, and Bacillus atrophaeus can survive for more than 6 days up to 210 days at maximum.

The Bioresearch team of the Company checked bacterial residue inside filters, and then based on the outcome, the team also conducted a ‘virus filtration test (virus passage test).’ After spraying ‘Phi X 174’ virus which is similar to the Covid-19 virus in size and features at a chamber of 60 m3, air purifiers from Company A, B, and C were operated for 10 minutes, respectively. Then, the virus level was measured around the purifier’s outlet area, and virus level was confirmed at 0.005~0.01% compared to the sprayed virus concentration in the air. One virus can multiply up to 1 million to 100 million times at maximum in 5~6 hours, and even if air purifier filter is used, 10,000 viruses, amounting to 0.01%, may not be filtered and may disperse into the air. Usually, as a small number of viruses such as 1,000 flu (influenza) viruses and 10~100 Noroviruses can cause infection, a sterilization system to prevent any micro leakage is required. It has been measured that one droplet of a Covid-19 patient contains 100-1,000 viruses at maximum.

Young Ju Lee, CEO of Seoul Viosys Co., Ltd. said, “Through this test, it has been confirmed that as time goes by, filters can even work as a medium of bacteria growth, and viruses that pass the filter can spread the infection. Filters alone cannot prevent bacterial infection and sterilization will be the best way for disinfection.”

With its dedication to UV LED technology development for the last 20 years, the Company has developed a clean sterilization technology, ‘Violeds.’ As part of the activities to prevent the spread of infection through the air, in 2020, the Company has provided ‘air sterilizers’ for free in 300 SOHO business sites in Korea that combine filters with ‘Violeds’ technology, developed based on the investment of KRW one billion. According to a phone survey on its users in December 2022, 92% of respondents were found to be satisfied, and 83% said they would recommend the product to others, showing that the level of satisfaction with the product is quite high.

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “WICOP Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths range (200nm to 1600nm) including ultraviolet rays (UV), visible rays and infrared rays. It holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for strong sterilization and disinfection (UVC), skin regeneration (UVB), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add the advanced VCSEL technology which supports smartphone facial recognition and autonomous driving, and has started its mass production. In January 2020, it introduced a disruptive “WICOP Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/, YouTube, Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Seoul Semiconductor Co., Ltd.
Jinseop Jung
+82-1566-2771
jjs8732@seoulsemicon.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

HiddenA line styled icon from Orion Icon Library.Eye